ArticlePloS one2009
Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00454545 (Atorvastatin in Moderate Active Crohns Disease), which is not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Atorvastatin in Moderate Active Crohns Disease
Who cites it
38 citing papers in PubMed, 76 citations in OpenAlex.
- Fenofibrate as an Adjunct Therapy for Ulcerative Colitis: Targeting Inflammation via SIRT1, NLRP3, and AMPK Pathways: A Randomized Controlled Pilot Study.Drug design, development and therapy · 2024Trial
- Atorvastatin in Combination With Narrowband UV-B in Adult Patients With Active Vitiligo: A Randomized Clinical Trial.JAMA dermatology · 2018Trial
- Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis and rheumatism · 2011Trial
- Chemokine CXCL10 and Incident Stroke Risk in the Northern Manhattan Study.Translational stroke research · 2026Article
- Statin Use is Associated with a Less Severe Disease Course In Inflammatory Bowel Disease: A Nationwide Cohort Study 2006-2020.Inflammatory bowel diseases · 2025Article
- Molecular and Immunomodulatory Mechanisms of Statins in Inflammation and Cancer Therapeutics with Emphasis on the NF-κB, NLRP3 Inflammasome, and Cytokine Regulatory Axes.International journal of molecular sciences · 2025Review
- The adjunctive role of metformin in patients with mild to moderate ulcerative colitis: a randomized controlled study.Frontiers in pharmacology · 2025Article
- Article
- Effect of a high dose atorvastatin as adjuvant therapy to mesalamine in attenuating inflammation and symptoms in patients with ulcerative colitis: a randomized controlled pilot study.Frontiers in medicine · 2024Article
- Pleotropic effects of statins: the dilemma of wider utilization of statin.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2023Review
- CCL13 and human diseases.Frontiers in immunology · 2023Review
- Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.Physiological reviews · 2022Review
- Identifying hub genes and miRNAs in Crohn's disease by bioinformatics analysis.Frontiers in genetics · 2022Article
- Systematic Review and Meta-Analysis of the Effect of Statins on Circulating E-Selectin, L-Selectin, and P-Selectin.Biomedicines · 2021Review
- Computational drug repositioning of atorvastatin for ulcerative colitis.Journal of the American Medical Informatics Association : JAMIA · 2021Article
- Association Between Statin Use and Inflammatory Bowel Diseases: Results from a Swedish, Nationwide, Population-based Case-control Study.Journal of Crohn's & colitis · 2021Article
- The role of chemokines and adipokines as biomarkers of Crohn's disease activity: a systematic review of the literature.American journal of translational research · 2021Review
- Article
- The C-C Chemokine Receptor Type 4 Is an Immunomodulatory Target of Hydroxychloroquine.Frontiers in pharmacology · 2020Article
- Analysis of the immunological biomarker profile during acute Zika virus infection reveals the overexpression of CXCL10, a chemokine linked to neuronal damage.Memorias do Instituto Oswaldo Cruz · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Crohn's disease high tissue expression and serum levels of chemokines and their receptors are known to correlate with disease activity. Because statins can reduce chemokine expression in patients with coronary diseases, we wanted to test whether this can be achieved in patients with Crohn's disease. METHODOLOGY/PRINCIPAL
findingsWe investigated plasma levels of chemokines (CCL2, CCL4, CCL11, CCL13, CCL17, CCL22, CCL26, CXCL8, CXCL10) and endothelial cytokines (sP-selectin, sE-selectin, sICAM-3, thrombomodulin) in ten Crohn's disease patients before and after thirteen weeks' daily treatment with 80 mg atorvastatin. Of the 13 substances investigated, only CXCL10 was found to be significantly reduced (by 34%, p = 0.026) in all of the treated patients. Levels of CXCL10 correlated with C-reactive protein (r = 0.82, p<0.01). CONCLUSIONS/SIGNIFICANCE: CXCL10 is a ligand for the CXCR3 receptor, the activation of which results in the recruitment of T lymphocytes and the perpetuation of mucosal inflammation. Hence the reduction of plasma CXCL10 levels by atorvastatin may represent a candidate for an approach to the treatment of Crohns disease in the future.
trial registration(ClinicalTrials.gov) NCT00454545.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.